Erk 1/2 and survivin could contribute to imatinib resistance in CML cell line independent of Bcr-Abl
| dc.contributor.author | Silva, Danielle Cardoso da | |
| dc.contributor.author | Moreira, Miguel Angelo Martins | |
| dc.contributor.author | Maia, Raquel Ciuvalschi | |
| dc.contributor.author | Vasconcelos, Flavia da Cunha | |
| dc.date.accessioned | 2021-12-06T16:24:51Z | |
| dc.date.available | 2021-12-06T16:24:51Z | |
| dc.date.issued | 2016 | |
| dc.identifier.uri | http://sr-vmlxaph03:8080/jspui/handle/123456789/4730 | |
| dc.publisher | INCA | pt_BR |
| dc.title | Erk 1/2 and survivin could contribute to imatinib resistance in CML cell line independent of Bcr-Abl | pt_BR |